Background: Cardiovascular event rates in patients with diabetes mellitus (DM) are significantly greater than that observed in those without DM. We evaluated the impact of glycemic control on the composite end point of CV death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for unstable angina and revascularization in patients with established DM treated with statin.Methods: The ACCELERATE trial randomized 12,092 subjects at high cardiovascular risk treated with high dose (46%) or moderate dose (50%) statin with baseline LDL of 81± 28 mg/dl and HDL 45 ± 12 mg/dL to treatment with Evacetrapib or placebo. We estimated KM events rates censored at 30 months in subjects with established DM at study baseline.Results: At study onset 8236 subjects had established type 2 DM. Estimated KM event rates in subjects with DM were significantly higher than in 3466 non DM (15.2 vs, 10.2%; p= <0.001). Amongst subjects with DM, baseline HbA1c levels were strongly predictive of CV outcomes with increasing baseline HbA1c associated with increased CV risk (p<0.001) (Fig). The all-cause mortality was similar regardless of baseline HbA1c levels (p=0.18).Conclusion: Despite a baseline LDL of 81± 28 mg/dl and statin therapy, HbA1c levels remained strongly associated with CV outcomes in high risk patients with diabetes.